About DNDi
DNDi is a company based in Geneve (Switzerland) founded in 2003. Developer of treatments for neglected tropical diseases. Its website dndi.org draws about 60 thousand monthly visits. DNDi offers products and services including Treatments for Neglected Diseases and Advocacy and Policy Services. Its legal entity is Drugs for Neglected Diseases initiative.
Company details
DNDi was founded in 2003 in Geneva, Switzerland, as a non-profit organization focused on the pharmaceutical sector for neglected diseases. Research and development efforts are directed toward clinical trials and registration of accessible medicines targeting low- and middle-income countries. Global partnerships are maintained to address diseases such as sleeping sickness, Chagas disease, and leishmaniasis. Advocacy for policy improvements is conducted, alongside work on pandemic preparedness and antimicrobial resistance.
- InvestorsHHS
& 1 more
Products & Services of DNDi
DNDi offers a comprehensive portfolio of products and services, including Treatments for Neglected Diseases and Advocacy and Policy Services.
Treatments are developed for diseases like sleeping sickness and Chagas disease to address severe health issues in underserved populations.
Advocacy is conducted for policy changes and equitable R&D to improve access to medicines for people in need worldwide.
Apps and channels of DNDi
its YouTube channel Drugs for Neglected Diseases initiative (DNDi) has 84.6K subscribers and 30 videos.
Videos from DNDi
The most watched videos on DNDi's YouTube channel, Drugs for Neglected Diseases initiative (DNDi) (84.6K subscribers). Click a video to play it here.
Funding Insights of DNDi
- Total Rounds 5
- First Round $1.09M
(Aug 2007)
- Investors Count 2
All 5 funding rounds of DNDi with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2023 | Grant | – | – | ||
| Sep 2019 | $2.51M | Grant | – | – | |
| Sep 2010 | $1.24M | Grant | – | – | |
| Sep 2009 | $1.09M | Grant | – | – | |
| Aug 2007 | $1.09M | Grant | – | – |
2 investors in total: 2 institutional.
Investors in DNDi
DNDi has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for DNDi
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of DNDi
77 people are tracked at DNDi (27 in leadership, 50 in team).
| Name | Role | Group |
|---|---|---|
Dr Luis Pizarro | Executive Director | Leadership |
Nathalie Strub Wourgaft | Medical Director | Leadership |
Laurence Vielfaure | Director Of Finance | Leadership |
James Arkinstall | Director Of Communications | Leadership |
Wendy Keller | Head Of Clinical Quality Assurance At Drugs For Neglected Diseases Initiative - Dndi | Leadership |
Phoutthasone Bouppha | Head Of Financial Control | Leadership |
Dominique Junod Moser | Director Of Legal Affairs | Leadership |
Pascal Carpentier | Information Systems And Technology Director | Leadership |
Valérie Cayron-Elizondo | Head Of Drug Safety & Pharmacovigilance | Leadership |
Isabela Ribeiro | Director, Viral Diseases Cluster | Leadership |
Byron Arana | Head Of Cutaneous Leishmaniasis Programme | Leadership |
Anderson Leal | HR And Organization Director | Leadership |
Charles Mowbray | Discovery Director | Leadership |
Frederic Monnot | Clinical Operations Director | Leadership |
Eric Chatelain | Head Of Drug Discovery - Member Of The Senior Leadership Team | Leadership |
María-Jesús Pinazo Delgado | Head Of Chagas | Leadership |
Delali A. | Regional Executive Director, Dndi North America | Leadership |
Carol Ruffell | Head Of Joint Office, Southern Africa | Leadership |
Michelle Childs | Director Policy Advocacy | Leadership |
Jean-Yves Gillon | Head Of Translational Sciences | Leadership |
57 more people are available in the full profile.
Complete people profiles for DNDi
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of DNDi
3 dated milestones of DNDi across 20 years, from founding to its latest funding, stage changes and deals.
- Founded DNDi is founded.
- Funding First funding round of $1.1M.
- Funding Latest funding round, Grant,.
Web traffic of DNDi
The website of DNDi (dndi.org) receives about 60K visits a month.
- Monthly visits60K
▼ 43.1% vs previous month
Websites whose visitors overlap most with DNDi. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| mmv.org | 100% | 78.8K | #509,335 | View details | |
ghtcoalition.org | ghtcoalition.org | 76% | #3,059,585 | – | |
| tballiance.org | 70% | #2,264,008 | View details | ||
ngdi.ubc.ca | ngdi.ubc.ca | 67% | – | ||
| newtbdrugs.org | 66% | #3,185,292 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 22 similar websites and full traffic analytics for DNDi
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 22 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about DNDi
DNDi was founded in 2003 and raised its 1st funding round 4 years after it was founded.
DNDi is headquartered in Geneve, Switzerland. It is registered at Geneve, Geneve, Switzerland.
DNDi was founded in 2003 in Geneva, Switzerland, as a non-profit organization focused on the pharmaceutical sector for neglected diseases. Research and development efforts are directed toward clinical trials and registration of accessible medicines targeting low- and middle-income countries. Global partnerships are maintained to address diseases such as sleeping sickness, Chagas disease, and leishmaniasis. Advocacy for policy improvements is conducted, alongside work on pandemic preparedness and antimicrobial resistance.
DNDi offers Treatments for Neglected Diseases and Advocacy and Policy Services.
DNDi has 2 investors. Key investors include HHS, and European Union.
DNDi operates through Drugs For Neglected Diseases Initiative.